Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.

TitleQuality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
Publication TypeJournal Article
Year of Publication2019
AuthorsNagarajan R, Gerbing R, Alonzo TA, Johnston DL, Aplenc R, Kolb EA, Meshinchi S, Barakat LP, Sung L
JournalCancer Med
Date Published2019 Jun 12
ISSN2045-7634
Abstract

INTRODUCTION: Objectives were used to describe guardian proxy-report and child self-report quality of life (QoL) during chemotherapy for pediatric acute myeloid leukemia (AML) patients.

METHODS: Patients enrolled on the phase 3 AML trial AAML1031 who were 2-18 years of age with English-speaking guardians were eligible. Instruments used were the PedsQL Generic Core Scales, Acute Cancer Module, and Multidimensional Fatigue Scale. Assessments were obtained at the beginning of Induction 1 and following completion of cycles 2-4. Potential predictors of QoL included the total number of nonhematological grade 3-4 Common Terminology Criteria for Adverse Event (CTCAE) submissions.

RESULTS: There were 505 eligible guardians who consented to participate and 348 of their children provided at least one self-report assessment. The number of submitted CTCAE toxicities was significantly associated with worse physical health summary scores (β ± standard error (SE) -3.00 ± 0.69; P < 0.001) and general fatigue (β ± SE -2.50 ± 0.66; P < 0.001). Older age was significantly associated with more fatigue (β ± SE -0.58 ± 0.25; P = 0.022). Gender, white race, Hispanic ethnicity, private insurance status, risk status, bortezomib assignment, and duration of neutropenia were not significantly associated with QoL.

DISCUSSION: The number of CTCAE toxicities was the primary factor influencing QoL among children with AML. Reducing toxicities should improve QoL; identifying approaches to ameliorate them should be a priority.

DOI10.1002/cam4.2337
Alternate JournalCancer Med
PubMed ID31190442
Grant List / / St. Baldrick's Foundation /
UG1CA189955 / / National Cancer Institute at the National Institute of Health's Community Oncology Research Program (NCORP) Research Base /
U10CA098543 / / Chair's /
U10CA098413 / / Statistics & Data Center /
U10CA180886 / / National Clinical Trials Network Operations Center /
U10CA180899 / / National Clinical Trials Network Statistics & Data Center /